Compare iShares Core High Dividend ETF (HDV) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core High Dividend ETF vs TransMedics Group Inc — how do they compare? iShares Core High Dividend ETF trades at $28.71 (market cap $14.68B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: iShares Core High Dividend ETF is far larger — about 5.4× TransMedics Group Inc's market cap, and iShares Core High Dividend ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core High Dividend ETF for 117 Days and TransMedics Group Inc for 24 Days on average.
| HDV | TMDX | |
|---|---|---|
Market Cap | $14.68B | $2.74B |
Volume | 2,925,562 | 949,331 |
52-Week High | $29.93 | $150.42 |
52-Week Low | $23.64 | $61.99 |
Typical Hold Time | 117 Days | 24 Days |
Sector | — | Health |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDV (iShares Core High Dividend ETF) trades at $28.71, up 1.52% with a bullish technical signal. Recent sector rebalancing reduced healthcare exposure by nearly half while increasing energy, staples, and utilities, creating concentration risk with 62% in three sectors. The ETF yields approximately 3% but faces questions about whether this compensates for reduced diversification. Technical indicators show strong momentum with RSI at 77.74 suggesting potential overbought conditions.
The outlook remains cautiously optimistic given HDV's 2026 outperformance against the S&P 500, though the concentrated sector allocation and moderate yield present both opportunity and risk. Investors should weigh the fund's recent structural changes against its dividend income generation capabilities in a rising rate environment.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
